Roderick Brown, DO
Gastroenterology · McComb, MSNPI 1215391354
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 339 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 30.1% of the total. 2025 is the largest year on record at $2,175, more than ten times the $71 reported in 2019.
Across 339 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$726
- Takeda Pharmaceuticals U.S.A., Inc.$505
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$438
- Gilead$360
- Aimmune Therapeutics, Inc.$327
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,58399%
- Education$681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 110 | $2,000 |
| Johnson & Johnson(2 entities) | 36 | $726 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $505 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $438 |
| Gilead | 11 | $360 |
| Aimmune Therapeutics, Inc. | 11 | $327 |
| QOL Medical, LLC | 16 | $301 |
| Ardelyx, Inc. | 14 | $260 |
| Pfizer | 13 | $251 |
| Bristol Myers Squibb | 9 | $169 |
| Regeneron Healthcare Solutions, Inc. | 6 | $159 |
| Intercept Pharmaceuticals, Inc. | 9 | $158 |
| Sanofi | 10 | $154 |
| Phathom Pharmaceuticals, Inc. | 8 | $147 |
| Madrigal Pharmaceuticals | 6 | $111 |
| Merck | 5 | $101 |
| Mahana Therapeutics, Inc. | 1 | $73 |
| AstraZeneca | 1 | $68 |
| Evoke Pharma, Inc. | 3 | $56 |
| Cook Medical LLC | 2 | $52 |
| Lilly USA, LLC | 3 | $47 |
| Novartis | 3 | $43 |
| Janssen Scientific Affairs, LLC | 1 | $32 |
| Redhill Biopharma Inc. | 2 | $26 |
| Novo Nordisk | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Fresenius Kabi USA, LLC | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$125
How this compares
$6,651 in reported general payments places this provider in the 60th percentile of 127 gastroenterology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 11 | $38,623 |
| LinzessLinaclotide | 46 | $35,167 |
| TrulancePlecanatide | 13 | $9,672 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 33 | $5,574 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 23 | $1,604 |
| Sucralfate | 21 | $1,167 |
| Omeprazole | 74 | $827 |
| Dicyclomine Hcl | 49 | $734 |
| Pantoprazole Sodium | 48 | $613 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 15 | $497 |
| Ondansetron OdtOndansetron | 13 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,000 | $73,79057 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $438 | $9,67213 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $14 | $5,57433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 127 gastroenterology providers in Mississippi.
Other gastroenterology in McComb
- Stephen KeithMcComb$9K
- Wassem JuakiemBiloxi$519K
- Reed HoganFlowood$216K
- John PhillipsTupelo$150K
- Brian BorgJackson$68K
- Pegah Hosseini-CarrollJackson$62K
- Shou Jiang TangJackson$50K
- Vonda ReevesFlowood$39K
- Ernest WilliamsOxford$38K
- Reed HoganFlowood$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.